公开(公告)号：US20240239879A1

公开(公告)日：2024-07-18

申请号：US18440895

申请日：2024-02-13

Applicant: Xencor, Inc.

Inventor： Aaron Keith Chamberlain ,  Bassil Dahiyat ,  John R. Desjarlais ,  Sher Bahadur Karki ,  Gregory Alan Lazar

IPC: C07K16/18 ,  A61K39/00 ,  C07K14/715 ,  C07K16/08 ,  C07K16/22 ,  C07K16/24 ,  C07K16/28 ,  C07K16/32 ,  C07K16/42

CPC classification number: C07K16/18 ,  C07K14/7151 ,  C07K16/082 ,  C07K16/22 ,  C07K16/241 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/2893 ,  C07K16/2896 ,  C07K16/32 ,  C07K16/4291 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/90 ,  C07K2319/30 ,  Y02A50/30

Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.

公开(公告)号：US11932685B2

公开(公告)日：2024-03-19

申请号：US17079299

申请日：2020-10-23

Applicant: Xencor, Inc.

Inventor： Aaron Keith Chamberlain ,  Bassil Dahiyat ,  John R. Desjarlais ,  Sher Bahadur Karki ,  Gregory Alan Lazar

IPC: C07K16/00 ,  A61K39/395 ,  C07H21/04 ,  C07K14/715 ,  C07K16/08 ,  C07K16/18 ,  C07K16/22 ,  C07K16/24 ,  C07K16/28 ,  C07K16/32 ,  C07K16/42 ,  C12N1/20 ,  C12N5/00 ,  C12N5/16 ,  C12N15/00 ,  A61K39/00

CPC classification number: C07K16/18 ,  C07K14/7151 ,  C07K16/082 ,  C07K16/22 ,  C07K16/241 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/2893 ,  C07K16/2896 ,  C07K16/32 ,  C07K16/4291 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/90 ,  C07K2319/30 ,  Y02A50/30

Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.

公开(公告)号：US11851466B2

公开(公告)日：2023-12-26

申请号：US17062458

申请日：2020-10-02

Applicant: Xencor, Inc.

Inventor： Matthew Bernett ,  John R. Desjarlais ,  Rajat Varma ,  Ke Liu ,  Rumana Rashid ,  Nargess Hassanzadeh-Kiabi ,  Michael Hedvat

IPC: C07K16/46 ,  C07K14/54 ,  A61P35/00 ,  C07K16/28 ,  A61K39/00

CPC classification number: C07K14/5434 ,  A61P35/00 ,  C07K16/2818 ,  C07K16/2827 ,  A61K2039/505 ,  C07K2317/622 ,  C07K2319/30

Abstract: The present invention relates to targeted IL-12 heterodimeric Fc fusion proteins, where the fusion proteins bind to human PD-1 or human PD-L1.

公开(公告)号：US20230340144A1

公开(公告)日：2023-10-26

申请号：US18172196

申请日：2023-02-21

Applicant: XENCOR, INC.

Inventor： Matthew J. Bernett ,  Seung Yup Chu ,  John R. Desjarlais ,  Sher Bahadur Karki ,  Gregory Alan Lazar ,  Erik Weiking Pong ,  John O. Richards ,  Eugene Alexander Zhukovsky

IPC: C07K16/28

CPC classification number: C07K16/2896 ,  C07K16/2803 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94

Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcγR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.

公开(公告)号：US20230227560A1

公开(公告)日：2023-07-20

申请号：US17819218

申请日：2022-08-11

Applicant: Xencor, Inc.

Inventor： Seung Yup Chu ,  John R. Desjarlais ,  Sher Bahadur Karki ,  Gregory Alan Lazar ,  Gregory L. Moore ,  Igor Vostiar

IPC: C07K16/28 ,  C07K16/00

CPC classification number: C07K16/283 ,  C07K16/00 ,  C07K16/2803 ,  C07K16/2851 ,  C07K16/2878 ,  C07K2317/52 ,  C07K2317/24 ,  C07K2317/524 ,  C07K2317/53 ,  C07K2317/71 ,  C07K2317/72 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/77 ,  A61K2039/505

Abstract: The present invention relates to immunoglobulins that bind FcγRIIb+ cells and coengage the antigen on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.

公开(公告)号：US20220227867A1

公开(公告)日：2022-07-21

申请号：US17561613

申请日：2021-12-23

Applicant: Xencor, Inc.

Inventor： Matthew J. Bernett ,  John R. Desjarlais ,  Gregory Moore ,  Suzanne Schubbert

IPC: C07K16/28 ,  C07K14/54 ,  C07K14/715 ,  C12N15/63

Abstract: The present invention is directed to novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15Rα Fc-fusion protein and a ICOS antibody fragment-Fc fusion protein.

公开(公告)号：US11377477B2

公开(公告)日：2022-07-05

申请号：US16600236

申请日：2019-10-11

Applicant: Xencor, Inc.

Inventor： Matthew Bernett ,  John R. Desjarlais ,  Michael Hedvat ,  Suzanne Schubbert ,  Christine Bonzon ,  Rumana Rashid ,  Rajat Varma

IPC: C07K16/28 ,  A61K39/395 ,  C07K14/28 ,  C12N15/63 ,  C07K14/54 ,  A61K38/00

Abstract: The present invention is directed to novel PD-1 targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15Rα Fc-fusion protein and a PD-1 antibody fragment-Fc fusion protein. In some embodiments, the PD-1 targeted IL-15/Rα-Fc fusion proteins are administered to a patient to treat cancer. In some embodiments, the PD-1 targeted IL-15/Rα-Fc fusion proteins are administered in combination with a PD-1 blockade antibody such as nivolumab and/or pembrolizumab. In some embodiments, the PD-1 targeted IL-15/Rα-Fc fusion proteins do not compete with a PD-1 blockade antibody such as nivolumab and/or pembrolizumab for antigen binding.

公开(公告)号：US11358999B2

公开(公告)日：2022-06-14

申请号：US16592656

申请日：2019-10-03

Applicant: Xencor, Inc.

Inventor： Matthew Bernett ,  John R. Desjarlais ,  Rajat Varma ,  Ke Liu ,  Nargess Hassanzadeh-Kiabi ,  Rumana Rashid

IPC: C07K14/54 ,  C07K19/00 ,  C07K1/18 ,  A61K38/20 ,  A61K38/00

Abstract: The present invention provides novel IL-12 Fc fusion proteins, methods of making and using the same. The IL-12. Fc fusion proteins are useful for treatment of cancer and can be used in combination with checkpoint blockade.

公开(公告)号：US20220144956A1

公开(公告)日：2022-05-12

申请号：US17520590

申请日：2021-11-05

Applicant: Xencor, Inc.

Inventor： John R. Desjarlais ,  Gregory Moore ,  Suzanne Schubbert ,  Alex Nisthal

IPC: C07K16/28 ,  C12N15/63

Abstract: Provided herein are novel antibodies that bind TGFßRII and methods of making and using such antibodies. The antibodies provided advantageously block TGFß activity in a broad population of cells (e.g., active and unactivated hematopoietic cells), and find use wherein such blockage of TGFß activity is desirable, for example, for the treatment of cancers. In some embodiments, the antibodies are novel αTGFßRII×αCD5 and αTGFßRII×αPD-1 bispecific antibodies.

公开(公告)号：US20210115118A1

公开(公告)日：2021-04-22

申请号：US16830063

申请日：2020-03-25

Applicant: Xencor, Inc.

Inventor： Aaron Keith Chamberlain ,  Bassil Dahiyat ,  John R. Desjarlais ,  Sher Bahadur Karki ,  Gregory Alan Lazar

IPC: C07K16/18 ,  C07K14/715 ,  C07K16/08 ,  C07K16/22 ,  C07K16/24 ,  C07K16/28 ,  C07K16/32 ,  C07K16/42

Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.